Table 6. Multivariate survival analysis of clinicopathological factors in 86 patients with EC.
| Variable | Univariate analysis crude HR (95% CI) | Multivariate adjusted HR (95% CI) |
|---|---|---|
| Age (years) | 1.05 (1.02–1.08)** | 1.05 (1.02–1.10)** |
| TET1 expressiona | ||
| Low | 1.00 (Ref.) | 1.00 (Ref.) |
| High | 0.34 (0.14–0.85)* | 0.31 (0.11–0.84)* |
| 5-hmC expressionb | ||
| Low | 1.00 (Ref.) | |
| High | 0.80 (0.37–1.73) | – |
| 5-mC expressionc | ||
| Low | 1.00 (Ref.) | |
| High | 1.98 (0.59–6.58) | – |
| FIGO stage | ||
| I, II | 1.00 (Ref.) | 1.00 (Ref.) |
| III, IV | 8.41 (3.28–21.58)** | 7.70 (2.72–21.76) ** |
| Nuclear grade | ||
| G1 | 1.00 (Ref.) | |
| G2 | 0.82 (0.27–2.44) | – |
| G3 | 3.26 (1.38–7.74)** | – |
| Histological type | ||
| Type I EC (EmAC G1 and G2) | 1.00 (Ref.) | 1.00 (Ref.) |
| Type II EC (EmAC G3, MC, CC, and SC) | 3.52 (1.62–7.63)** | 3.46 (1.37–8.74)** |
a Low expression of TET1 is represented as ≤20; high expression of TET1 is represented as >20.
b Low expression of 5-hmC is represented as ≤80; high expression of 5-hmC is represented as >80.
c Low expression of 5-mC is represented as ≤270; high expression of 5-mC is represented as >270.
* p < 0.05
** p < 0.01. CC, clear cell carcinoma; CI, confidence interval; EC, endometrial carcinoma; EmAC, endometrioid adenocarcinoma; HR, hazard ratio; MC, mucinous carcinoma; Ref., reference group; SC, serous carcinoma.